Translucence Biosystems presents research at AD/PD™ 2022, Alzheimer's & Parkinson's Diseases Conference

by
Damian Wheeler
March 30, 2022

Dear Collegues,

Translucence Biosystems was honored to present at the AD/PD™ 2022, Alzheimer's & Parkinson's Diseases Conference. Please see our poster presentation entitled, "Brain-Wide Cellular Resolution Measurement of Neuronal Activity, Microglial Activation and β-Amyloid Deposition" below.

Abstract

Recent advances in optical clearing and light sheet imaging have opened an exciting new avenue for brain-wide, cellular resolution immunostaining at the forefront of a dimensional shift from 2D to 3D histology. With access to the intricate anatomy of the whole intact brain, we are developing unbiased and complete pictures of brain pathology for pre-clinical studies.

Methods: With our optimized iDISCO-based clearing methods and our Mesoscale Imaging System for the ZEISS Lightsheet Z.1 microscope, we can image entire mouse brains in ~10 min. Further, our machine learning-enabled 3TK software identifies individual cells or protein aggregates throughout the brain and aligns them to the Allen Reference Atlas to produce a regionalized read-out of patterns across 100’s of brain areas.

Results: We have applied this technology to generate cellular resolution maps of neuronal activity by measuring the immediate-early gene (IEG) products Npas4 and cFos in response to both a light exposure task and in response to contextual fear conditioning. Further, we have optimized methods to identify and count microglia throughout the brain and perform regional analyses of microglial activation.

Importantly, we have used Alzheimer’s Disease model 5xFAD mice to develop assays to generate brain-wide signatures of β-Amyloid deposition. Our automated analysis of microglia and β-Amyloid co-staining allows for brain-wide quantification of plaque-associated microglia. Conclusions: These new methods for whole-brain, next generation 3D immunohistochemistry and anatomics are ideally suited to pre-clinical studies for unbiased, complete and anatomically precise mapping of the efficacy of CNS therapeutics. We thank NIMH for Grants R43MH119989 and R43MH122070.

Ask your question

Send us your questions and we will get back to you as soon as possible
info@translucencebio.com

Thank you! Your submission has been received!
Something went wrong while submitting the form.
Please, contact via us direct email info@translucencebio.comand

Recent news

August 8, 2024
Updates

Accelerating Alzheimer's Research: Translucence Biosystems at the Alzheimer's Association International Conference® (AAIC24)

Translucence Biosystems recently presented at the Alzheimer's Association International Conference® (AAIC24) in Philadelphia. Co-Founder & CEO, Damian Wheeler, Ph.D., and expert Chase Redd shared tools, technologies, and 3D histology techniques that are accelerating Alzheimer's research.
by
Translucence Biosystems
January 30, 2024
Updates

Highlights from the 21st Advanced Imaging Methods (AIM) Workshop

Translucence Biosystems recently attended and sponsored the 21st Advanced Imaging Methods (AIM) Workshop, hosted by The Berkeley Cancer Research Laboratory Molecular Imaging Center (MIC) from January 23-25, 2024.
by
Angela Prvulovic
January 25, 2024
Updates

Connecting with Tissue Clearing Enthusiasts at the Harvard Center for Biological Imaging (HCBI) Tissue Clearing Workshop

It was great to connect with fellow tissue clearing enthusiasts at the HCBI Tissue Clearing Workshop hosted by the Harvard Center for Biological Imaging. CEO Damian G. Wheeler and expert Chase Redd had an opportunity to discuss with attendees how the Translucence Biosystems team is generating tools and technologies for making 3D tissue clearing and AI-powered analysis accessible to all researchers.
by
Translucence Biosystems